These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL; Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562 [TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Merryman RW; Redd RA; Taranto E; Ahmed G; Jeter E; McHugh KM; Brown JR; Crombie JL; Davids MS; Fisher DC; Freedman AS; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Jacene H; Park H; Dahi PB; Nieto Y; Joyce RM; Chen YB; Shipp MA; Herrera AF; Armand P Blood Adv; 2023 Sep; 7(17):4748-4759. PubMed ID: 36399518 [TBL] [Abstract][Full Text] [Related]
9. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441 [TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Merryman RW; Redd RA; Nishihori T; Chavez J; Nieto Y; Darrah JM; Rao U; Byrne MT; Bond DA; Maddocks KJ; Spinner MA; Advani RH; Ballard HJ; Svoboda J; Singh AK; McGuirk JP; Modi D; Ramchandren R; Romancik J; Cohen JB; Frigault MJ; Chen YB; Serritella AV; Kline J; Ansell S; Nathan S; Rahimian M; Joyce RM; Shah M; David KA; Park S; Beaven AW; Habib A; Bachanova V; Nakhoda S; Khan N; Lynch RC; Smith SD; Ho VT; LaCasce A; Armand P; Herrera AF Blood Adv; 2021 Mar; 5(6):1648-1659. PubMed ID: 33710337 [TBL] [Abstract][Full Text] [Related]
11. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260 [TBL] [Abstract][Full Text] [Related]
12. Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma. Zhang C; Deng J; Xie Y; Mi L; Liu W; Wang X; Zhao L; Song Y; Zhu J Cancer Med; 2023 May; 12(9):10351-10362. PubMed ID: 37081731 [TBL] [Abstract][Full Text] [Related]
14. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Armand P; Zinzani PL; Lee HJ; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Herrera AF; Lin J; Kim E; Chakraborty S; Marinello P; Moskowitz CH Blood; 2023 Sep; 142(10):878-886. PubMed ID: 37319435 [TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study. Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937 [TBL] [Abstract][Full Text] [Related]
16. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101 [TBL] [Abstract][Full Text] [Related]
17. Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial. Liu Y; Ping L; Song Y; Tang Y; Zheng W; Liu W; Ying Z; Zhang C; Wu M; Feng F; Lin N; Tu M; Zhu J; Xie Y BMC Med; 2024 Mar; 22(1):107. PubMed ID: 38454451 [TBL] [Abstract][Full Text] [Related]
18. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Sauter CS; Senechal B; Rivière I; Ni A; Bernal Y; Wang X; Purdon T; Hall M; Singh AN; Szenes VZ; Yoo S; Dogan A; Wang Y; Moskowitz CH; Giralt S; Matasar MJ; Perales MA; Curran KJ; Park J; Sadelain M; Brentjens RJ Blood; 2019 Aug; 134(7):626-635. PubMed ID: 31262783 [TBL] [Abstract][Full Text] [Related]
19. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694 [TBL] [Abstract][Full Text] [Related]
20. Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma. Lee L; Alrasheed N; Khandelwal G; Fitzsimons E; Richards H; Wilson W; Chavda SJ; Henry J; Conde L; De Massy MR; Chin M; Galas-Filipowicz D; Herrero J; Chain B; Quezada SA; Yong K Front Immunol; 2021; 12():618610. PubMed ID: 33717112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]